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New agents with potential leishmanicidal 
activity identified by virtual 
screening of chemical databases
Nuevos agentes con potencial actividad leishmanicida 
identificados mediante tamizaje virtual
New agents with potential leishmanicidal activity
Juan Rebollo, BS1, Jesús Olivero-Verbel, PhD2, Niradiz Reyes, PhD1
ABSTRACT
Introduction and Objectives: Leishmaniosis, a disease caused by a protozoan parasite, remains a serious 
public health problem threatening about 350 million people around the world, of which 12 million are 
believed to be currently infected (WHO 2010). To date, there are no vaccines against the species of 
parasites and the treatment is based only on chemotherapy with toxic-, expensive- and inefficient- drugs. 
There is an urgent need for better drugs against Leishmania, the etiological agent of the disease. The 
main anti-leishmanial drug used in Colombia is meglumineantimoniate [chemical name according to the 
International Union of Pure and Applied Chemistry (IUPAC): Hydroxy-dioxostiborane; (2R,3R,4R,5S)-
6-methylaminohexane-1,2,3,4,5-pentol, (C7H17NO5)], which is not efficient in the treatment of infections 
caused by Leishmania braziliensis, the most prevalent specie in the Caribbean coast of Colombia. Methods: 
We performed an in silico virtual screening of several datasets including ChemBridge and Pubchem. 
We virtually screened a total of 28.755 compounds against a 3D model of 6-phosphoglucono -lactonase 
(6-PGL) from Leishmania braziliensis to identify novel inhibitors.Molecular docking of databases was 
performed using the software Sybyl 8.0 and AutoDockVina. Results: The initial virtual screening using a 
structure-based method identified 10 compounds, which were later tested with AutodockVina and classified 
according to their docking scores. Conclusions: These novel and potential inhibitors constitute new drug 
candidates that must be biologically tested to define their value as an alternative chemotherapeutic agent in 
the treatment of these protozoan infections. Salud UIS 2013; 45 (1): 33-40
Keywords: leishmaniosis, virtual screening, therapeutics, molecular docking simulation, drug search.
Evidence level: III
RESUMEN
Introducción y Objetivos: Leishmaniosis, una enfermedad causada por un parásito protozoario, representa 
un serio problema de salud pública que amenaza a cerca de 350 millones de personas alrededor del mundo, 
de los cuales se cree que unos 12 millones se encuentran actualmente infectados (WHO 2010). A la fecha 
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no existen vacunas contra las especies del parásito y el tratamiento está basado solo en la quimioterapia con 
medicamentos tóxicos, costosos, e ineficientes. Existe una necesidad urgente por mejores medicamentos 
contra Leishmania, el agente etiológico de la enfermedad. El principal medicamento en Colombia usado 
contra la leishmaniosis es el antimoniato de meglumine [nombre químico según los parámetrosde la 
International Union of Pure and Applied Chemistry (IUPAC): Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-
methylaminohexane-1,2,3,4,5-pentol, (C7H17NO5)], el cual no es eficiente en el tratamiento de infecciones 
causadas por Leishmania braziliensis, la especie más prevalente en la costa Caribe de Colombia. Métodos: 
En este trabajo efectuamos un tamizaje virtual in silico de varias bases de datos incluyendo ChemBridge 
y Pubchem. Con el objetivo de identificar nuevos inhibidores, un total de 28.755 compuestos fueron 
tamizados virtualmente contra un modelo 3D de la enzima 6-phosphoglucono –lactonase (6-PGL) de 
Leishmania braziliensis. El acoplamiento molecular de las bases de datos se efectuó con el programa Sybyl 
8.0 y AutoDock Vina. Resultados: mediante tamizaje virtual basado en la estructura se identificaron10 
compuestos, los cuales fueron posteriormente evaluados con AutodockVina y clasificados de acuerdo a 
los puntajes de acoplamiento. Conclusiones: Estos nuevos potenciales inhibidores constituyen candidatos 
a medicamentos que deben ser evaluados biológicamente para definir su valor como alternativas 
quimioterapéuticas en el tratamiento de estas infecciones parasíticas. Salud UIS 2013; 45 (1): 33-40 
Palabras clave: leishmaniosis, tamizaje virtual, terapéutico, biblioteca virtual, base de datos.
Nivel de evidencia: III
INTRODUCTION
Leishmaniosis is a disease caused by protozoan 
parasites of the genus Leishmania1. It is considered 
by the World Health Organization (WHO) as a serious 
public health problem threatening about 350 million 
people in 88 countries around the world of which 
12 million are believed to be currently infected2. 
Leishmaniosis has been classified as endemic in 
98 countries or territories, including tropical and 
subtropical regions of Africa, Asia, Europe, North, 
Central and South America3. In Colombia, the disease 
is a growing problem, reported by the National Institute 
of Health with about 15 000 new cases in 20104, and 
the appearing of new sources of transmission reflect 
an increase in the spread of Leishmania (L.) strains5.
There are no vaccines against these parasites and the 
approaches to control the vector are not effective. The 
main line of defense against the disease is chemotherapy 
which is not efficient against the different species of 
the parasite, and patients commonly suffer toxic side 
effects, including heart, kidney, liver and gastrointestinal 
failure; worsened by the long time drug administration 
and the increasing parasite resistance. In addition, 
Meglumine antimoniate [chemical name according to 
the International Union of Pure and Applied Chemistry 
(IUPAC): Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-
methylaminohexane-1,2,3,4,5-pentol, (C7H17NO5)], 
the first line of treatment currently used in Colombia6, has 
led to progressive rise in treatment failure7-10.On the other 
hand, Miltefosine, a drug effective against infections 
caused by L. panamensis, is not effective against 
infections produced by L. braziliensis (cure rates below 
50%)11, which is the most prevalent specie reported in 
the Caribbean region of the country12. Thus, there is an 
urgent need for new drugs against this parasite. Despite 
this situation, leishmaniosis is still a neglected tropical 
disease (NTDs) 13 prevalent in developing countries and 
poor populations14. Therefore, implementation of rational 
and cost effective approaches to treat this health problem 
is required. In this regard, virtual screening, and in 
particular receptor-based virtual screening, has emerged 
as a reliable, inexpensive method for identifying leads 
15, and the in silico screening of chemical databases to 
search for new compounds against Leishmania would 
allow us to identify specific inhibitors of target molecules 
of the parasite.
The current study describes a rational scheme in the 
quest for new Leishmania targets, through the study 
of its biochemical pathways, and shows the potential 
of structure based virtual screening to identify novel 
compounds with inhibitory activity against essential 
target enzymes from the parasite using computer aided 
molecular docking of databases16,17.
MATERIAL AND METHODS
Selection of target proteins
To carry out virtual screening using molecular docking, 
we first selected the most appropriate target protein of 
the parasite, which met the following selection criteria: 
the putative target should be involved in a biochemical 
pathway essential for survival of the parasite cell; it 
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should have low homology to its counterpart in the 
human host; and it may have a suitable three dimensional 
model in Protein Data Bank (PDB).
Potential targets were identified through a systematic 
search of relevant scientific literature on Leishmania 
metabolism indexed in MEDLINE database and 
retrieved through PubMed search engine, using key 
words “Leishmania metabolism”, “Leishmania drug 
targets” and “Leishmania metabolic pathways”.
Homology of each selected protein to their human 
counterpart was determined with the PSI-BLAST 
program from the European Bioinformatics Institute 
(EMBL-EBI).
Modeling the three dimensional structure of 
selected targets
A search for the three dimensional structure of each 
protein on Protein Data Bank (PDB) was performed. For 
proteins lacking a defined three-dimensional structure, 
experimental models were developed with integrated 
SYBYL8.0 Orchestra, and the servers I-TASSER 18, 
EsyPred3d 19 and 3D-JigSaw 20.
In order to select the best model, the 3D structure of 
each potential target was assessed by ProQ-Protein 
Quality Predictor Server, SWISS-MODEL and SAVES, 
a meta-server for analysis and verification of models.
 
Selection of compound datasets
Diverse chemical datasets used in the study were 
obtained from ChemBridge Corporation portfolio 
and PubChem database, containing 20.000 and 8.755 
compounds, respectively. Molecules from PubChem 
were selected based on their structural relationship 
with the natural ligands of selected protein targets from 
Leishmania. SDF files available online and containing 
two dimensional coordinates of the compounds were 
downloaded for each collection, and a Sybyl database 
was built. 
Protein and ligand preparation
The protein chosen in our study was the 
6-phosphoglucono- lactonase (6-PGL) from L. 
braziliensis. The three dimensional structure of 6-PGL 
from Leishmania braziliensis (PDB ID: 3CH7) resolved 
by X-ray diffraction at 2.29 Å was downloaded from the 
Protein Data Bank. The protein was edited, converted 
to mol2 format and processed for docking procedure 
using the Sybyl docking interface. Water molecules 
were removed before docking simulation, the protomol 
was built through the automatic mode and confirmed 
by alignment with the already determined active site of 
6-PGL from Trypanosoma brucei (PDB ID: 3E7F). For 
the Vina based docking, 6-PGL was processed with the 
Autodock tools (ADT) software, water moleculeswere 
removed, polar hydrogen atoms added and Kollman 
charges assigned.
The ligand datasets in SDF format were converted to a 
Sybyl database in mol2 format and each compound was 
minimized by Sybyl energy minimizer using the Tripos 
force field and Gasteiger-Hückel charges. The maximum 
number of interactions was set to 100 and the minimization 
was terminated by the Powell method, when the energy 
gradient of 0.05 kcal/mol/Å was reached.
The analysis by AutodockVina required the conversion 
of the ligands and protein to the PDBQT format, which 
is the input format for AutoDockVina calculations.
Structure Based Virtual screening
Virtual screening of 28.755 compounds against the 3D 
structure of 6-PGL was performed with the Surflex-Dock 
application coupled in Sybyl 8.0. The ligands were later 
classified according to the total score and the best docked 
compounds (Total Score > 8) were selected for testing 
using the AutoDockVina software. The selected ligands 
were docked to a rigid receptor limited by the coordinates 
of the grid, which was defined using the ADT application 
and the exhaustiveness of the docking was set to nine. 
Each compound was docked individually. The best 
dockings were manually inspected and their interactions 
with the receptor were described.
RESULTS AND DISCUSSION
Selection of target proteins
A rational approach to search and design new anti-
leishmanial compounds must select a suitable target 
protein, which should be essential for the parasite 
survival and as different as possible from its human 
counterpart. A systematic review of the literature 
searching for potential target molecules involved in 
Leishmania metabolism identified five enzymes as 
potential targets for drugs. These biochemical targets 
are involved in glycolysis (phosphofructokinase and 
pyruvate kinase), the pentose phosphate pathway 
(6-phosphogluconolactonase), nucleotide metabolism 
(dihydrofolatereductase) and antioxidants (tryparedoxin 
peroxidase), all of them considered essential for the 
survival of Leishmania21,22. 
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Enzymes involved in glycolysis appear to be 
appropriate therapeutic targets because they are 
essential for the amastigote form of the parasite. 
In addition, there is a huge evolutionary distance 
between Leishmania and Homo sapiens that make the 
parasite proteins, involved in this pathway, structurally 
different from their mammalian equivalents23. The 
phosphofructokinase (PFK), an enzyme present in the 
amastigote form of Leishmania, participates in this 
biochemical pathway, catalyzing the phosphorylation 
of fructose-6-phosphate (F6P) to produce fructose 
1,6-bisphosphate24 and is structurally different from 
the human PFK, a feature useful for the  designing of 
specific inhibitors ofits biological function. On the other 
hand, pyruvate kinase (PyK) catalyzes the conversion 
of phosphoenol pyruvate (PEP) to pyruvate to produce 
ATP. This enzyme is allosterically regulated by fructose 
2,6-bisphosphate, which induces the conversion to the 
active state of the protein22. Studies that compared the 
PyK crystal structure of the parasite withthe PyKof 
other organisms have identified important differences 
between these enzymes at the level of its effector site 
revealing unique regulatory properties for the parasite 
enzyme, which could be a potential target for drugs25,26.
The trypanothione metabolism is another biochemical 
pathway with potential targets; the enzyme 
tryparedoxin peroxidase (TryP) is a key molecule 
in the defense mechanism against oxidative stress27. 
This enzyme is responsible for the removal of reactive 
oxygen intermediates such as superoxide anion 
(O2
-), hydrogen peroxide (H2O2), peroxynitrite 
(ONOO-) and hydroxyl radical (OH-) produced during 
the process of cellular respiration. Furthermore, studies 
with mutants of L. donovani and L. major lacking a 
functional trypanothione reductase have established 
that this enzyme is essential for parasite survival28. 
Another important enzyme that protects Leishmania 
from toxic radicals is the 6-Phosphogluconolactonase 
from the pentose phosphate pathway. It converts 
6-phosphogluconolactone to 6-phosphogluconate 
maintaining a source of NADPH, which serves to protect 
against oxidative stress and generates carbohydrate 
intermediates used in nucleotide and other biosynthetic 
pathways. Furthermore, the loss of this enzyme has 
been shown to be toxic for the parasite, making it a 
suitable target for chemotherapy29.
Modeling the three dimensional structure of 
selected targets
The only enzyme reported in the PDB with a three-
dimensional structure defined by X-ray diffraction 
was the 6-Phosphogluconolactonase. For the other 
enzymes, it was necessary to build their three-
dimensional models from the amino acid sequence 
of each protein through different modeling programs 
(I-TASSER, 3D-JigSaw and Orchestra, included in 
Sybyl 8.0). After evaluation of each model by the meta 
server SAVS (Structural Analysis and Verification 
Server), the most suitable model was selected for 
docking analysis. Considering the quality of the three-
dimensional model retrieved from the PDB and the 
three basic characteristics that a target must satisfy 
(Table 1), the protein and model chosen was the 
6-PGL from L. braziliensis.
Tabla 1. Evaluation of the protein target models through multiple servers.
Target source: l. braziliensis (Method)
Meta server Evaluation Identity 
with human 
homologuePro-Q* PROCHECK† verify_3d‡
Pyruvate kinase (PyrK) PREDICTION ESYPRED 5.521 86.8% core 12.2% allow 0.2% disall 95.10% Pass 48.5%
6-phosphoglucono lactonase 
(6-PGL) X-RAY DIFFRACTION 7.616
93.2% core 6.4% 
allow 0.0% disall 96.25% Pass 30%
Phosphofructokinase (PFK) PREDICTION ESYPRED 6.144 94.6% core 4.9% allow 0.3% disall 83.48% Pass 33.6%
Tryparedoxin peroxidase 
(TRYP1) PREDICTION ESYPRED 4.542
94.6% core 5.4% 
allow 0.0% disall 88.27% Pass 59.9%
Dihydrofolate Reductase-
Thymidylate synthase (DHFR-
TS)
PREDICTION ESYPRED 5.887 73.0% core 23.0% allow 0.9% disall 79.89% Fail 60.6%
* ProQLGscore:an score >1.5 is a fairly good model; >2.5, very good model; >4, extremely good model30.
† Procheck description of the Ramachandran Polt for each model, where “core” means the percentage of residues in the most favored region, 
“allow” is the percentage of residues in additional allowed regions and “disall” represent residues in disallowed regions.
‡ Verify 3D score showsthe percentage of residues having an averaged 3D-1D score > 0.231,32
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Virtual Screening
Structure-based virtual screening was carry out to 
predict the binding affinity of 28.755 molecules from 
a diverse chemical library, in order to identify novel 
drug-like inhibitors of 6-PGL from Leishmania. This 
method involved computational docking of ligands into 
an active site of a receptor using complex algorithms, 
followed by scoring and ranking of these compounds 
to identify potential leads. Compared to ligand- or 
pharmacophore- based method, the receptor-based 
method of screening is a more flexible approach that 
allows the identification of structurally novel ligands 
that may have similar interactions to those of known 
ligands, or may have different interactions with other 
parts of the binding site33.
The first screening, performed with Sybyl 8.0 program, 
provided a set of 11 candidate molecules, which bound 
to the receptor with the higher affinities (Total Score 
> 8) (Table 2). These ligands were later docked to the 
6-PGL through the AutodockVina program to validate 
the binding affinities and to sort them according to 
their docking scores (Table 2).Compounds listed in 
this table could be considered as potential leads on 
the light of virtual docking, but should be tested in 
vitro or in vivo assays to confirm their real potential as 
anti-leishmanial drugs. Figure 1 shows the molecular 
docking of compound L1 with the active site of 6-PGL 
from Leishmania; the ligand is maintained in the active 
site by a set of intermolecular forces that include polar 
interactions and hydrogen bonds.
Tabla 2. Compounds ranked according to sybul and Autbdock Vina Scores.
Compound sybyl 8.0 Total score Autodock vina score (kcal/mol) structure
L1 8.33 -7.8
L2 9.05 -7.3
L3 8.02 -7.2
L4 10.17 -7.1
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Compound sybyl 8.0 Total score Autodock vina score (kcal/mol) structure
L5 10.44 -7.0
L6 11.32 -7.0
L7 8.12 -6.8
L8 10.02 -6.6
L9 8.11 -6.5
L10 9.79 -6.5
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Figure 1. Docking-predicted poses and interactions between 
compounds L1 (upper panels) and L2 (bottom panels) with 
the active site of the 6-PGL protein from L. braziliensis. Polar 
interactions and hydrogen bonds are shown as yellow dotted 
lines; ligands are represented in stick and residues of the 
active site as lines labeled in orange with the 3 letters amino 
acid code. The remaining of the protein in shown as cartoon 
representation (left panels) and the protein surface is shown in 
orange (right panles).
CONCLUSIONS
Structure-based virtual screening allowed us to 
identify a set of potential anti-leishmanial compounds 
through a computer-aided drug discovery approach;we 
screened in silico a diverse and large library of 28755 
compounds against 6-PGL protein, a vital enzyme 
for Leishmania survival. Ligands bounded with 
higher affinity to the receptor protein were subjected 
to docking validation and ranked through the 
AutodockVina docking score function.
We consider that compounds identified represent 
candidates for testing as potential therapeutic 
agents against leishmaniosis. However, the real 
leishmanicidal activity of these compounds should be 
biologically evaluated before they can be proposed 
as anti-leishmanial drugs. Nevertheless, by this 
computer-aided screening we have identified from 
a large chemical database, the leads with the higher 
likelihood of binding to the target protein to elicit an 
inhibitory activity, which would reduce the cost of 
biological testing.
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